Over the past two decades, the treatment of active psoriatic arthritis (PsA) has been transformed by targeted biologic therapies. In this ReCAP, Dr Eric Ruderman, from the Feinberg School of Medicine at Northwestern University, reports on the safety and efficacy of several approved therapies.
Dr Ruderman first discusses different treatment options, including TNF inhibitors, which have been the standard first-line therapy for nearly two decades. He also reports that other agents, including Il-12/23 inhibitors abatacept, apremilast, and a number of JAK inhibitors, have shown efficacy for patients who don’t respond well or are intolerant to TNF inhibitors.
In recent years, various specific IL-23 inhibitors have been approved to treat psoriasis and, most recently, psoriatic arthritis in psoriasis. Guselkumab, risankizumab, and tildrakizumab were approved to treat the skin disease.
In psoriatic arthritis, guselkumab and risankizumab have also been approved. These drugs have shown more efficacy than the IL-12/23 inhibitor, according to Ruderman, and show a lower risk for infection compared with some of the other agents.
--
Eric M. Ruderman, MD, Professor, Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine; Associate Division Chief, Clinical Affairs, Department of Rheumatology, Northwestern Medical Group, Chicago, Illinois
Eric M. Ruderman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Amgen; Bristol Myers Squibb; Janssen; Lilly; Merck; Novartis; NS Pharma; UCB